Full Text
PCN100 Cost Utility Analysis of Bortezomib in a Biomarker Positive Subgroup of Relapsed and Refractory Folicular Lymphoma

Abstract

Authors

S. Vandekerckhove M. Lamotte S. Iannazzo O. Chirita

Back to Volume 15, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×